Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge

Merck & Co., Inc.

2025-FY EPS reported $7.28 revenue$65,011,000,000

Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).
Full-year sales $65.0B; Non-GAAP EPS $8.98 (+17% YoY).
KEYTRUDA $31.7B (+7%); WINREVAIR $1.4B; GARDASIL $5.2B (-39% on China weakness).
FY2026 sales guidance $65.5-$67.0B; Non-GAAP EPS $5.00-$5.15 includes ~$3.65 Cidara charge.
Acquired Verona Pharma and Cidara; 18 positive Phase 3 trials in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.